Vertex Pharma (VRTX) Tops Q1 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Vertex (VRTX) Q1 Quiet, But Reimbursement Commentary 'Encouraging'; Leerink Says; PT Up to $150
April 30, 2015 6:18 AM EDTLeerink Partners analyst Howard Liang reiterated an Outperform rating and boosted his price target on Vertex (NASDAQ: VRTX) to $150.00 (from $131.00) following a "quiet" quarter as reimbursement commentary was encouraging.
Liang commented, "VRTX reported roughly in-line Kalydeco sales for 1Q:15 ($130M vs. our/consensus estimates of $127M/$131M).... More
